Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 58% ± 16% | |
peripheral blood | 18 studies | 35% ± 13% | |
intestine | 13 studies | 45% ± 17% | |
brain | 12 studies | 34% ± 13% | |
eye | 10 studies | 47% ± 23% | |
kidney | 9 studies | 60% ± 12% | |
liver | 8 studies | 45% ± 18% | |
uterus | 6 studies | 58% ± 18% | |
lymph node | 6 studies | 50% ± 20% | |
pancreas | 5 studies | 48% ± 19% | |
bone marrow | 5 studies | 30% ± 10% | |
placenta | 4 studies | 74% ± 25% | |
esophagus | 4 studies | 56% ± 30% | |
prostate | 4 studies | 75% ± 14% | |
breast | 4 studies | 67% ± 4% | |
ovary | 3 studies | 47% ± 6% | |
heart | 3 studies | 29% ± 13% | |
adipose | 3 studies | 28% ± 7% | |
adrenal gland | 3 studies | 47% ± 6% | |
skin | 3 studies | 52% ± 23% | |
thymus | 3 studies | 66% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 14930.10 | 1445 / 1445 | 100% | 466.38 | 183 / 183 |
ovary | 100% | 6528.91 | 180 / 180 | 100% | 352.91 | 430 / 430 |
breast | 100% | 8845.86 | 459 / 459 | 100% | 560.85 | 1116 / 1118 |
uterus | 100% | 7260.32 | 170 / 170 | 100% | 521.59 | 457 / 459 |
liver | 100% | 8524.71 | 225 / 226 | 100% | 382.37 | 406 / 406 |
thymus | 100% | 17841.01 | 653 / 653 | 100% | 485.18 | 602 / 605 |
lung | 100% | 9871.21 | 577 / 578 | 100% | 607.37 | 1151 / 1155 |
stomach | 100% | 8576.42 | 359 / 359 | 99% | 417.45 | 284 / 286 |
intestine | 100% | 8390.60 | 966 / 966 | 99% | 409.85 | 523 / 527 |
bladder | 100% | 9677.00 | 21 / 21 | 98% | 491.93 | 496 / 504 |
prostate | 100% | 6799.49 | 244 / 245 | 99% | 276.59 | 495 / 502 |
kidney | 100% | 13009.89 | 89 / 89 | 98% | 309.90 | 879 / 901 |
brain | 100% | 9013.39 | 2637 / 2642 | 94% | 360.72 | 665 / 705 |
skin | 100% | 10184.04 | 1807 / 1809 | 94% | 385.64 | 442 / 472 |
adrenal gland | 100% | 10794.79 | 258 / 258 | 85% | 150.03 | 195 / 230 |
pancreas | 60% | 1617.37 | 197 / 328 | 97% | 301.73 | 173 / 178 |
adipose | 100% | 8298.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 664.91 | 29 / 29 |
muscle | 100% | 10555.02 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7665.01 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 541.05 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 253.55 | 1 / 1 |
blood vessel | 100% | 9451.84 | 1331 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 376.08 | 79 / 80 |
heart | 94% | 9026.93 | 812 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 61% | 5068.72 | 564 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045454 | Biological process | cell redox homeostasis |
GO_1901222 | Biological process | regulation of non-canonical NF-kappaB signal transduction |
GO_0008283 | Biological process | cell population proliferation |
GO_0033554 | Biological process | cellular response to stress |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0030101 | Biological process | natural killer cell activation |
GO_0042744 | Biological process | hydrogen peroxide catabolic process |
GO_0045321 | Biological process | leukocyte activation |
GO_0032872 | Biological process | regulation of stress-activated MAPK cascade |
GO_0042267 | Biological process | natural killer cell mediated cytotoxicity |
GO_0034101 | Biological process | erythrocyte homeostasis |
GO_0048144 | Biological process | fibroblast proliferation |
GO_0001501 | Biological process | skeletal system development |
GO_0019430 | Biological process | removal of superoxide radicals |
GO_0006979 | Biological process | response to oxidative stress |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0042470 | Cellular component | melanosome |
GO_0005634 | Cellular component | nucleus |
GO_0004601 | Molecular function | peroxidase activity |
GO_0008379 | Molecular function | thioredoxin peroxidase activity |
GO_0045296 | Molecular function | cadherin binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PRDX1 |
Protein name | Peroxiredoxin-1 (EC 1.11.1.24) (Natural killer cell-enhancing factor A) (NKEF-A) (Proliferation-associated gene protein) (PAG) (Thioredoxin peroxidase 2) (Thioredoxin-dependent peroxide reductase 2) (Thioredoxin-dependent peroxiredoxin 1) thioredoxin-dependent peroxiredoxin (EC 1.11.1.24) Peroxiredoxin-1 (Thioredoxin-dependent peroxiredoxin 1) |
Synonyms | PAGB TDPX2 PAGA |
Description | FUNCTION: Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2) . Reduces an intramolecular disulfide bond in GDPD5 that gates the ability to GDPD5 to drive postmitotic motor neuron differentiation (By similarity). . |
Accessions | ENST00000447184.6 ENST00000676549.1 ENST00000262746.5 Q06830 ENST00000372079.1 ENST00000447184 ENST00000424390.2 A0A0A0MSI0 A0A0A0MRQ5 ENST00000319248.13 ENST00000424390 |